Analysis Of The Subjective Comfort In 115 First-episode Schizophrenia Patients Were Taking The Second Generation Of Antipsychotic Drugs

BackgroundSchizophrenia is often thought, perception, emotion and behavior and other aspects of the disorder of unknown etiology. It has a prolonged course.Since the second generation antipsychotics, such as risperidone, aripiprazole, olanzapine, ziprasidone, are widely used, their clinical generally believe that they have good tolerance and safety. However, the goal of drug therapy is not only improve psychiatric symptoms, but also improve cognitive function and compliance, improve the quality of life, promote the return to society etc.. Antipsychotic drugs in the treatment of subjective comfort (SWN) refers to the antipsychotic drug treatment, all the experiences and feelings of psychiatric symptoms, patient reported physical, emotional and cognitive level, for the assessment of patients in the drug treatment of subjective feelings. The SWN scale of the establishment to the present, the domestic and foreign studies have shown that it has good reliability and validity, however, domestic research and psychiatrists long neglected the subjective experience of patients with antipsychotic drugs.ObjectiveFocusing on the four antipsychotics aforementioned, to explore the changes in SWN and compliance in the inpatients of schizophrenia using the second generaton ones.MethodsThe qualified subjects were enrolled and randomly assigned to four groups, respectively. Subjective Well-being on neuroleptics scale and Drug Attitude Inventory (DAI) were used to assess the changes in respective targeted category in the subjects. Simultaneously, using the positive and negative symptoms scale (PANSS) and treatment need to deal with adverse reactions of symptoms rating scale (TESS), the symptomatology changes and adverse drug reactions were measured. All the data got in this study were analyzed by SPSS20.0 software.Results1 Different treatment groups SWN scores were compared: each group of patients before treatment SWN score difference was no difference (F=0.678, P=0.567); the treatment 6 weeks in patients with SWN scores were increased, compared with before treatment, there was statistically significant (P<0.05); SWN scores were increased in all groups, the largest increase was the average ratio of aripiprazole group, treatment increased before 28.33±9.51, olanzapine group increased at least, 17.83±16.24; Compared between groups before and after treatment SWN score, the difference was statistically significant (F=3.704, P=0.014); multiple comparison, olanzapine and ziprasidone group and aripiprazole group, there were statistically significant differences between risperidone group and aripiprazole group (P<0.05); but there was no statistical difference in each of the remaining differences between the two groups (P>0.05).2 Different treatment groups DAI scores were compared:each group of patients before treatment DAI score difference was no statistically significant (F=0.361, P=0.782); for 6 weeks in patients with DAI score were increased, compared with before treatment, the difference was statistically significant (P<0.05); were compared between groups before and after treatment DAI score, there was no statistically significant difference (P>0.05).3 Different treatment groups PANSS scores were compared:each group of patients before treatment PANSS score difference was no statistically significant (F=0.480, P=0.697); the treatment 6 weeks in patients with PANSS score were decreased, compared with before treatment, the difference was statistically significant (P<0.01); were compared between groups before and after treatment PANSS score difference, no difference statistical significance (P>0.05).4 Different treatment groups TESS scores: 6 weeks of treatment, TESS scores showed that, olanzapine group was the highest (4.87±1.22), risperidone group (4.63 ±1.65), ziprasidone group was lower (2.87±1.01), aripiprazole group was the lowest (2.50±0.78). The group compared with 6 weeks of treatment, TESS score, the difference was statistically significant (F=29.894, P=0.000); there was no significant difference between olanzapine group and risperidone group, there was no statistically significant difference in ziprasidone group and aripiprazole group (P>0.05), and the difference was statistically significant between olanzapine and ziprasidone and risperidone group and aripiprazole group (P<0.05).5 SWN, PANSS 6 weeks of treatment, DAI,TESS score and Pearson correlation analysis: there was a negative correlation between SWN score and TESS score (r=-0.199, P=0.030), the rest of the two scores are not related.Conclusions1 single antipsychotic drugs after 6 weeks, subjective comfort were improved, medication compliance increased, clinical symptoms were improved.2 single antipsychotic drugs after 6 weeks, the subjective comfort: ziprasidone and aripiprazole than olanzapine, aripiprazole is superior to risperidone; medication attitude: Four no significant differences between drugs; mental symptom improvement: four kinds of drug efficacy. The side effects of Qi:lacidipine group and aripiprazole olanzapine and risperidone side reaction is small.3 After singly taking antipsychotic drugs for six weeks,it has a higher correlation between the side effects of drugs and subjective comfort.The smaller the side effects of antipsychotic drugs, patients with higher subjective comfort,prompting clinicians should fully consider the subjective comfort of patients after they take medication.At the same time of controlling the mental symptoms,as far as possible to choose the second generation antipsychotics with smaller side effects and higher subjective comfort,to improve the quality of the patients’life.